Thursday, February 07, 2008 3:05:14 PM
Ticker: IMYN
Board: http://investorshub.advfn.com/boards/board.asp?board_id=11789
Immunosyn Corporation
4225 Executive Square
Suite 260
La Jolla, CA 92037
United States - Map
Phone: 858-200-2320
Web Site: http://www.immunosyn.com
Detailed Quote for Immunosyn Corp. (IMYN)
$ 3.15
Shares Issued and Outstanding
272.0 m
Market Cap
856.8 m
Immunosyn Corporation, a development stage marketing and distribution company, plans to market and distribute life enhancing therapeutics. Its principal product includes SF-1019, which is targeted for the treatment of auto-immune disorders, such as Multiple Sclerosis; and neurological disorders, including Chronic Inflammatory Demyelinating Polyneuropathy and Reflex Sympathetic Dystrophy Syndrome, and complications from Diabetic Mellitus, such Diabetic Neuropathy and diabetic ulcers. The company was founded in 2006 and is headquartered in La Jolla, California. Immunosyn Corporation is a subsidiary of Argyll Biotechnologies, LLC.
OUR VISION Immunosyn’s Corporate Vision: SF-1019 and Beyond
At Immunosyn, we envision ourselves improving the quality of life of millions of people who suffer from painful and debilitating diseases, but every vision must have strategy in order to succeed - what follows is our strategy for achieving this vision
Our Primary Strategy
* Expand operations and establish a position in the market to be poised for distribution of SF-1019, upon its potential regulatory approval in the appropriate jurisdictions, and/or the distribution of other new products.
* Prepare to cultivate market awareness and acceptance of SF-1019 in the appropriate jurisdictions as a potential first line of defense by mainstream medical practitioners for the treatment of conditions related to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Diabetic Neuropathy (DN), Diabetic Ulcers (DU), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), also known as Complex Regional Pain Syndrome (CRPS), and to educate those affected by these diseases once SF-1019 has been proven to be effective and has received appropriate regulatory approvals.
* Build worldwide sales and distribution channels so that if and when SF-1019, or any other possible Immunosyn products, receive regulatory approval they can be sold and distributed without delay.
* Develop and execute diligent post sales support to ensure customer satisfaction and safety.
News:
LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN - News) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html
http://biz.yahoo.com/prnews/080131/lath062.html?.v=101
23-Jan-2008 FORM 8-K IMMUNOSYN ANNOUNCES THE SUCCESSFUL COMPLETION OF FIRST PHASE "PROOF OF CONCEPT TRIAL" IN EUROPE FOR TREATMENT OF DIABETIC ULCERS WITH BIOPHARMECEUTICAL SF-1019
http://biz.yahoo.com/e/080123/imyn.ob8-k.html
Friday January 18, 12:11 pm ET Stephen D. Ferrone, CEO of Immunosyn, to Present at Flaherty Financial News/Wall Street Research Conference
http://biz.yahoo.com/prnews/080118/laf055.html?.v=91
LA JOLLA, Calif., Jan. 17 Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
http://biz.yahoo.com/prnews/080117/lath111.html?.v=80
Research:
SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26342411
Science Behind SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451888
SF-1019: Other Areas of Potential Impact:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451935
Human Diseases Potentially Treatable with SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344576
Multiple Sclerosis (MS).(Disease/Disorder overview):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451492
Chronic inflammatory demyelinating polyneuropathy (CIDP):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451694
Reflex Sympathetic Dystrophy Syndrome (RSDS):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451780
Diabetic Neuropathy & Diabetic Ulcers:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26452174
Letter from Lt. Governor of Utah requesting FDA approval of SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344716
Letter from Alan Osmond:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344996
Alan Osmond's MS Story:
Alan Osmond Says MS Improving with Treatment
November 27th, 2007 @ 10:15pm
Carole Mikita reporting
Alan Osmond, the oldest of the singing Osmond brothers, is back doing just that: singing, playing the piano and composing. For years he has been battling multiple sclerosis, MS, but recently his physical deterioration has turned around.
Two and a half years ago, Alan Osmond could not lift his right arm and had such weakness in his right leg, he was using a wheelchair. His multiple sclerosis had progressed. He could no longer do what his family does.
In 1992 the Osmond brothers became a hit in Branson, but Alan stopped performing. Now he's back.He credits his faith, his wife and a new natural injection treatment called SF1019, or Immunosyn. Not yet FDA approved, he traveled to England to become part of a clinical trial.
"Could not pick up a penny, couldn't hold my grandkids. And I said, (he looks up) 'Help.' Two and a half years or so of taking the product, I can honestly say I am improving. I've still got MS, but MS doesn't have me," Alan said.
Suzanne Osmond says, "Anyone who has a compromised immune system, whether overactive or underactive, it helps."
Even his Utah neurologist is impressed. "This hand couldn't even move, now I'm doin' both hands. And he says, 'What are you doin'?' I said, 'I'm just dabbling.' He says, 'That is not placebo,' he said, ‘This stuff's workin'," Alan said.
Alan is not quite where his dancing sister is, but getting there. He says he's still improving and will join his famous siblings in their 50th anniversary world tour.
Alan Osmond's MS website: http://osmondms.com/
Want to know more about SF-1019?
Know someone who has MS and needs help?
Other Immune Challenges? Talk to Doctor?
Write to me (Alan Osmond) HERE (Write to me (Alan Osmond) HERE!
(osmondstrengtheningfamilies@gmail.com)
I am not a doctor but we want to stay in touch with those who need help with their MS and other immune System problems! We are working to get SF10-19 available for you very soon with great doctors! "Strengthening Families w/ One Heart!
About Alan Osmond (bio)
"Big Al's Story: http://investorshub.advfn.com/boards/read_msg.asp?message_id=26450344
See Videos (AMAZING):
Yes, I may still have M.S. but, M.S. does NOT have me!
Board: http://investorshub.advfn.com/boards/board.asp?board_id=11789
Immunosyn Corporation
4225 Executive Square
Suite 260
La Jolla, CA 92037
United States - Map
Phone: 858-200-2320
Web Site: http://www.immunosyn.com
Detailed Quote for Immunosyn Corp. (IMYN)
$ 3.15
Shares Issued and Outstanding
272.0 m
Market Cap
856.8 m
Immunosyn Corporation, a development stage marketing and distribution company, plans to market and distribute life enhancing therapeutics. Its principal product includes SF-1019, which is targeted for the treatment of auto-immune disorders, such as Multiple Sclerosis; and neurological disorders, including Chronic Inflammatory Demyelinating Polyneuropathy and Reflex Sympathetic Dystrophy Syndrome, and complications from Diabetic Mellitus, such Diabetic Neuropathy and diabetic ulcers. The company was founded in 2006 and is headquartered in La Jolla, California. Immunosyn Corporation is a subsidiary of Argyll Biotechnologies, LLC.
OUR VISION Immunosyn’s Corporate Vision: SF-1019 and Beyond
At Immunosyn, we envision ourselves improving the quality of life of millions of people who suffer from painful and debilitating diseases, but every vision must have strategy in order to succeed - what follows is our strategy for achieving this vision
Our Primary Strategy
* Expand operations and establish a position in the market to be poised for distribution of SF-1019, upon its potential regulatory approval in the appropriate jurisdictions, and/or the distribution of other new products.
* Prepare to cultivate market awareness and acceptance of SF-1019 in the appropriate jurisdictions as a potential first line of defense by mainstream medical practitioners for the treatment of conditions related to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Diabetic Neuropathy (DN), Diabetic Ulcers (DU), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), also known as Complex Regional Pain Syndrome (CRPS), and to educate those affected by these diseases once SF-1019 has been proven to be effective and has received appropriate regulatory approvals.
* Build worldwide sales and distribution channels so that if and when SF-1019, or any other possible Immunosyn products, receive regulatory approval they can be sold and distributed without delay.
* Develop and execute diligent post sales support to ensure customer satisfaction and safety.
News:
LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN - News) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html
http://biz.yahoo.com/prnews/080131/lath062.html?.v=101
23-Jan-2008 FORM 8-K IMMUNOSYN ANNOUNCES THE SUCCESSFUL COMPLETION OF FIRST PHASE "PROOF OF CONCEPT TRIAL" IN EUROPE FOR TREATMENT OF DIABETIC ULCERS WITH BIOPHARMECEUTICAL SF-1019
http://biz.yahoo.com/e/080123/imyn.ob8-k.html
Friday January 18, 12:11 pm ET Stephen D. Ferrone, CEO of Immunosyn, to Present at Flaherty Financial News/Wall Street Research Conference
http://biz.yahoo.com/prnews/080118/laf055.html?.v=91
LA JOLLA, Calif., Jan. 17 Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
http://biz.yahoo.com/prnews/080117/lath111.html?.v=80
Research:
SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26342411
Science Behind SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451888
SF-1019: Other Areas of Potential Impact:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451935
Human Diseases Potentially Treatable with SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344576
Multiple Sclerosis (MS).(Disease/Disorder overview):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451492
Chronic inflammatory demyelinating polyneuropathy (CIDP):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451694
Reflex Sympathetic Dystrophy Syndrome (RSDS):
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26451780
Diabetic Neuropathy & Diabetic Ulcers:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26452174
Letter from Lt. Governor of Utah requesting FDA approval of SF-1019:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344716
Letter from Alan Osmond:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=26344996
Alan Osmond's MS Story:
Alan Osmond Says MS Improving with Treatment
November 27th, 2007 @ 10:15pm
Carole Mikita reporting
Alan Osmond, the oldest of the singing Osmond brothers, is back doing just that: singing, playing the piano and composing. For years he has been battling multiple sclerosis, MS, but recently his physical deterioration has turned around.
Two and a half years ago, Alan Osmond could not lift his right arm and had such weakness in his right leg, he was using a wheelchair. His multiple sclerosis had progressed. He could no longer do what his family does.
In 1992 the Osmond brothers became a hit in Branson, but Alan stopped performing. Now he's back.He credits his faith, his wife and a new natural injection treatment called SF1019, or Immunosyn. Not yet FDA approved, he traveled to England to become part of a clinical trial.
"Could not pick up a penny, couldn't hold my grandkids. And I said, (he looks up) 'Help.' Two and a half years or so of taking the product, I can honestly say I am improving. I've still got MS, but MS doesn't have me," Alan said.
Suzanne Osmond says, "Anyone who has a compromised immune system, whether overactive or underactive, it helps."
Even his Utah neurologist is impressed. "This hand couldn't even move, now I'm doin' both hands. And he says, 'What are you doin'?' I said, 'I'm just dabbling.' He says, 'That is not placebo,' he said, ‘This stuff's workin'," Alan said.
Alan is not quite where his dancing sister is, but getting there. He says he's still improving and will join his famous siblings in their 50th anniversary world tour.
Alan Osmond's MS website: http://osmondms.com/
Want to know more about SF-1019?
Know someone who has MS and needs help?
Other Immune Challenges? Talk to Doctor?
Write to me (Alan Osmond) HERE (Write to me (Alan Osmond) HERE!
(osmondstrengtheningfamilies@gmail.com)
I am not a doctor but we want to stay in touch with those who need help with their MS and other immune System problems! We are working to get SF10-19 available for you very soon with great doctors! "Strengthening Families w/ One Heart!
About Alan Osmond (bio)
"Big Al's Story: http://investorshub.advfn.com/boards/read_msg.asp?message_id=26450344
See Videos (AMAZING):
Yes, I may still have M.S. but, M.S. does NOT have me!
Click here to visit:
Disclaimer: http://investorshub.advfn.com/boards/irp.aspx?userid=65709
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
